Company Analysis ОЗОН Фармацевтика
1. Summary
Advantages
- Dividends (0.3963%) are higher than the sector average (0.1982%).
- The company's current efficiency (ROE=21.72%) is higher than the sector average (ROE=19.67%)
Disadvantages
- Price (43.98 ₽) is higher than fair price (10.65 ₽)
- The stock's return over the last year (0%) is lower than the sector average (0%).
- Current debt level 31.34% has increased over 5 years from 0%.
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| ОЗОН Фармацевтика | Фармацевтика | Index | |
|---|---|---|---|
| 7 days | -6.5% | -1.9% | 0.2% |
| 90 days | -20.3% | -8% | -15.2% |
| 1 year | 0% | 0% | -12.3% |
OZPH vs Sector: ОЗОН Фармацевтика has slightly underperformed the "Фармацевтика" sector by 0% over the past year.
OZPH vs Market: ОЗОН Фармацевтика has outperformed the market by 12.35% over the past year.
Stable price: OZPH is not significantly more volatile than the rest of the market on "Московская биржа" over the last 3 months, with typical variations of +/- 5% per week.
Long period: OZPH with weekly volatility of 0% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (43.98 ₽) is higher than the fair price (10.65 ₽).
Price is higher than fair: The current price (43.98 ₽) is 75.8% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (6.26) is lower than that of the sector as a whole (13.66).
P/E vs Market: The company's P/E (6.26) is lower than that of the market as a whole (8.26).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.14) is lower than that of the sector as a whole (2.11).
P/BV vs Market: The company's P/BV (1.14) is lower than that of the market as a whole (1.36).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.13) is lower than that of the sector as a whole (1.98).
P/S vs Market: The company's P/S indicator (1.13) is higher than that of the market as a whole (1.06).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (4.09) is lower than that of the sector as a whole (6.72).
EV/Ebitda vs Market: The company's EV/Ebitda (4.09) is higher than that of the market as a whole (-2.38).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by 0% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (0%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0%).
5.4. ROE
ROE vs Sector: The company's ROE (21.72%) is higher than that of the sector as a whole (19.67%).
ROE vs Market: The company's ROE (21.72%) is higher than that of the market as a whole (13.17%).
5.5. ROA
ROA vs Sector: The company's ROA (11.02%) is higher than that of the sector as a whole (8.78%).
ROA vs Market: The company's ROA (11.02%) is higher than that of the market as a whole (7.28%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (16.32%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 0.3963% is higher than the average for the sector '0.1982%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0.3963% has been steadily paid over the past 7 years, DSI=0.83.
Weak dividend growth: The company's dividend yield 0.3963% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (32.64%) are at a comfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
9. Stocks forum ОЗОН Фармацевтика
9.1. Stocks forum - Latest comments
9.2. Latest Blogs
Потери инвесторов на SPO 😭
Акции Озон Фармы 💊 на прошлой неделе упали на 11% на новости об объявлении SPO по 42 рубля, правда есть нюанс - компания попутно объявила допэмиссию 🚫
Предлагаю сегодня поговорить о SPO и последних таких размещениях в России на которых инвесторы исключительно теряли деньги......
More
#5_событий_недели
Отмечу следующие события уходящей недели:
— ПМЭФ 🇷🇺. Элита собиралась на шабаш в Санкт-Петербурге, правда никаких значимых новостей оттуда не пришло для российских инвесторов...
Были попытки разгонять акции всякого шлака в лице Самолета/ДВМП/Пик, но не более того...
— Продажи в Китай 🇨🇳....
More
Близость рецессии одна из главных тем на ПМЭФ. Оптимизма становится меньше
Во время проведения ПМЭФ российский фондовый рынок обычно растет, но не в этот раз. Поток новостей оттуда расстраивает инвесторов. По итогам основной сессии индекс МосБиржи просел на 0,4% и составил 2780,69 п., индекс РТС потерял 0,1% - до 1116,12 п....
More
All blogs ⇨
